Table 2. Overall Pathologic Results in 82 Patients Enrolled in OpACIN and OpACIN-neo.
| Pathologic result | Median (IQR) |
|---|---|
| Total node count per node field | |
| Median (IQR) | 19 (12-31) |
| Neck | 62 (41-76) |
| Axilla | 22 (14-29) |
| Axilla plus neck | 73 (52-81) |
| Groin | 9 (8-17) |
| Epitrochlear fossa | 1 (NA) |
| Node count with signs of viable or treated tumor | |
| Median (IQR) | 1 (1-2) |
| Neck | 1 (1-2) |
| Axilla | 1 (1-1) |
| Axilla plus neck | 20 (18-22) |
| Groin | 1 (1-2) |
| Epitrochlear fossa | 1 (NA) |
| Response ILN, No. (%)a | |
| pCR | 34 (41) |
| near-pCR | 15 (18) |
| pPR | 11 (13) |
| pNR | 22 (27) |
| Response total node field, No. (%)a | |
| pCR | 34 (41) |
| near-pCR | 16 (20) |
| pPR | 10 (12) |
| pNR | 22 (27) |
| ILN concordant with total node field, No. (%)a | |
| Yes | 81 (99) |
| No | 1 (1) |
| ILN concordant with every individual node response, No. (%)a | |
| Yes | 79 (96) |
| No | 3 (4) |
Abbreviations: ILN, index lymph node; NA, not applicable; near-pCR, near pathologic complete response; OpACIN, Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients; OpACIN-neo, Optimal Neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab; pNR, pathologic nonresponse; pPR, pathologic partial response.
a
Percentages may not total 100 due to rounding.